Scientific Publications

Sensory neuronopathies (SNN) encompass diverse etiologies, with autoimmunity playing a major role through both cellular and humoral responses. To investigate the humoral autoantibody repertoire in autoimmune SNN, we conducted a retrospective cohort study using large Human Proteome-wide protein microarrays (HuProt 3.1, HuProt 4.0, ProtoArrays). We specifically analyzed immune system pathways targeted within the autoantigen repertoire (the autoantigenome).

• Link: https://www.sciencedirect.com/science/article/pii/S2589909025000127?via%3Dihub

N-Tox is a grossly understudied immune-related adverse event (irAE), despite its association with mortality (e.g. encephalitis) and morbidities (e.g. peripheral neuropathy). We reported that pre-treatment sera autoantibodies (auto-Abs) are implicated in the pathogenesis of irAEs (Johannet et al. CCR 2022). We here examined the rate and patterns of N-Tox in melanoma patients who received ICI in the adjuvant setting and whether baseline specific serum auto-Abs are associated with N-Tox.

• Link: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.2517

Of the three stages of cancer immunoediting (elimination, equilibrium and escape), the first stage, elimination, where the destruction of early cancer cells prevents them to progress to the subsequent stages of immunoediting and thus prevents cancer development, has been the least studied. Recent laboratory research suggests that autoantibodies (AAbs) play a role in the elimination stage, through recognition of either neoantigens or tumor-associated antigens (TAAs) present on transforming cells.

• Link: https://www.sciencedirect.com/science/article/abs/pii/S0306987725001185?via%3Dihub

The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, recurrent pregnancy morbidity, or nonthrombotic manifestations in the setting of persistent antiphospholipid antibodies (aPL), namely anti-β2 glycoprotein-I antibody (aβ2GPI), anticardiolipin antibody (aCL), and lupus anticoagulant (LAC). Around one-third of the APS patients had an isolated LAC positivity lacking aβ2GPI and aCL. This study aimed to identify novel autoantibodies in APS using protein microarray technology.

• Link: https://www.jrheum.org/content/52/Suppl_1/43.1

Background/Objectives: COVID-19 has been associated with a wide range of immune responses, including the production of autoantibodies, particularly in severe cases. This study investigates the IgG autoantibody responses in patients with varying severities of COVID-19 infection and compares these responses with vaccinated individuals. Methods: We utilized proteomic profiling to analyze autoantibody reactivity against a broad spectrum of proteins expressed in lymphoid and myeloid cell subsets in serum samples from severe and moderate COVID-19 patients, as well as vaccinated individuals who received the inactivated CoronaVac (Sinovac) vaccine.

• Link: https://www.mdpi.com/2076-393X/13/7/694

Subarachnoid neurocysticercosis (SANCC) is a condition manifested by chronic meningitis induced by infection with Taenia solium. We sought to determine if there is evidence of autoantibody production in SANCC and whether local production of autoantibodies could be driven by immunogenic homologues found in T. solium.

• Link: https://academic.oup.com/ofid/article/12/5/ofaf276/8126795

Autoantibodies have a substantial impact on human health ranging from autoimmune diseases to cancer diagnostics. Knowledge of the antigens recognized can allow for more accurate diagnostics, a better understanding of pathogeneses and thus improved prevention, as well as laying the foundation for the development of new therapies. A critical step to acquire this knowledge is to detect the exact self-antigens targeted by autoantibodies out of the pool of 20,000 human proteins against which reactivities could be observed.

• Link: https://www.sciencedirect.com/science/article/pii/S0022175925000766?via%3Dihub

The success of passive immunotherapies targeting Calcitonin gene-related peptide (CGRP) for managing migraine has prompted our efforts towards developing an active immunotherapy that induces the production of endogenous antibodies against CGRP. Achieving efficacious antibody titers via immunization could provide a more convenient and cost-effective treatment alternative to anti-CGRP monoclonal antibody (mAb) therapies. However, immunization against endogenous CGRP faces multiple challenges such as breaking immune tolerance, inducing sufficient antibody titers, and avoiding immune response-associated toxicity.

• Link: https://www.nature.com/articles/s43856-025-00870-2

Celastrol (CEL) is a natural pentacyclic triterpenoid demonstrating significant therapeutic properties against various diseases. However, the ambiguity of target information poses a significant challenge in transitioning CEL from a traditional remedy to a modern pharmaceutical agent. Recently, the emerging target discovery approaches of natural products have broadened extensive avenues for uncovering comprehensive target information of CEL and promoting its drug development. Herein, diverse target discovery strategies are overviewed for the pharmacological and toxicological studies of CEL, including chemical proteomics, protein microarray, degradation-based protein profiling, proteome-wide label-free approaches, network pharmacology, target-based drug screening, multi-omics analysis, and hypothesis-driven target confirmation.

• Link: https://onlinelibrary.wiley.com/doi/10.1002/EXP.20240247

Despite the success of immune checkpoint blockers (ICBs), predicting which patients will respond to treatment remains a significant challenge, particularly in those with advanced NSCLC. Some circulating antibodies may serve as indicators of a pre-existing antitumor adaptive immune response. This study investigated the potential of baseline serum antibodies as predictors of response and survival in patients with advanced NSCLC undergoing ICB, chemotherapy, or ICB + chemotherapy.

• Link: https://aacrjournals.org/cancerres/article/85/8_Supplement_1/6042/759856/Abstract-6042-Baseline-serum-level-of-IgG